Intervention

Antihistamine

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 6 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials6

Recruiting1

Common conditions7

Lead sponsors shown5

Clinical trials

6 shown

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)NCT05319730 · 2023-05-16

RECRUITING

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)NCT04548999 · 2020-12-03

ACTIVE_NOT_RECRUITING

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)NCT04544436 · 2020-11-26

ACTIVE_NOT_RECRUITING

Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerNCT04568902 · 2020-09-30

COMPLETED

Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)NCT03050866 · 2017-02-21

UNKNOWN

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)NCT02688985 · 2016-04-29

COMPLETED

Common conditions

Multiple Sclerosis2 Breast Neoplasms1 Circulating Tumor Cell1 Esophageal Squamous Cell Carcinoma1 Metastatic Prostate Cancer1 Multiple Sclerosis, Primary Progressive1 Relapsing Multiple Sclerorsis1

Leading sponsors

Hoffmann-La Roche 2 Eisai Co., Ltd. 1 Erasmus Medical Center 1 Genentech, Inc. 1 Merck Sharp & Dohme LLC 1

Trial status mix

ACTIVE_NOT_RECRUITING2

COMPLETED2

RECRUITING1

UNKNOWN1

Phase mix

PHASE33

PHASE12

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.